However, a recent review of 11 clinical studies, reported that 29%-100% of patients presented with the same KRAS mutation in both blood and tumor samples suggesting that blood samples may also be suitable for determining KRAS status [19-21]. This evidence concerns the gene KRAS and neoplasm.